Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0WK6V
|
|||
| Former ID |
DNCL002911
|
|||
| Drug Name |
PF-05231023
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Type-2 diabetes [ICD-11: 5A11; ICD-9: 250] | Phase 1 | [1] | |
| Company |
Pfizer
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Fibroblast growth factor-21 (FGF21) | Target Info | . | [2] |
| KEGG Pathway | MAPK signaling pathway | |||
| Ras signaling pathway | ||||
| Rap1 signaling pathway | ||||
| PI3K-Akt signaling pathway | ||||
| Regulation of actin cytoskeleton | ||||
| Pathways in cancer | ||||
| Melanoma | ||||
| Reactome | Facilitative Na+-independent glucose transporters | |||
| Glucose transport | ||||
| WikiPathways | Regulation of Actin Cytoskeleton | |||
| Aryl Hydrocarbon Receptor | ||||
| SREBP signalling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01923389) Multiple Dose Study Of PF-05231023 In Obese Adult Subjects. U.S. National Institutes of Health. | |||
| REF 2 | Mechanistic investigation of the preclinical pharmacokinetics and interspecies scaling of PF-05231023, a fibroblast growth factor 21-antibody protein conjugate. Drug Metab Dispos. 2015 Jun;43(6):803-11. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.